JP2024534947A5 - - Google Patents

Info

Publication number
JP2024534947A5
JP2024534947A5 JP2024515041A JP2024515041A JP2024534947A5 JP 2024534947 A5 JP2024534947 A5 JP 2024534947A5 JP 2024515041 A JP2024515041 A JP 2024515041A JP 2024515041 A JP2024515041 A JP 2024515041A JP 2024534947 A5 JP2024534947 A5 JP 2024534947A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
liquid pharmaceutical
use according
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534947A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/075402 external-priority patent/WO2023041524A2/en
Publication of JP2024534947A publication Critical patent/JP2024534947A/ja
Publication of JP2024534947A5 publication Critical patent/JP2024534947A5/ja
Pending legal-status Critical Current

Links

JP2024515041A 2021-09-16 2022-09-13 シヌクレイノパチーを治療するための組成物及び方法 Pending JP2024534947A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21197120.5 2021-09-16
EP21197120 2021-09-16
PCT/EP2022/075402 WO2023041524A2 (en) 2021-09-16 2022-09-13 Compositions and methods for treating synucleinopathies

Publications (2)

Publication Number Publication Date
JP2024534947A JP2024534947A (ja) 2024-09-26
JP2024534947A5 true JP2024534947A5 (cg-RX-API-DMAC7.html) 2025-09-05

Family

ID=78049153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515041A Pending JP2024534947A (ja) 2021-09-16 2022-09-13 シヌクレイノパチーを治療するための組成物及び方法

Country Status (12)

Country Link
US (6) US12077578B2 (cg-RX-API-DMAC7.html)
EP (1) EP4401770A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024534947A (cg-RX-API-DMAC7.html)
KR (1) KR20240055758A (cg-RX-API-DMAC7.html)
CN (1) CN117915952A (cg-RX-API-DMAC7.html)
AR (1) AR127054A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022348798A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230055A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024000753A1 (cg-RX-API-DMAC7.html)
IL (1) IL311344A (cg-RX-API-DMAC7.html)
MX (1) MX2024002970A (cg-RX-API-DMAC7.html)
WO (1) WO2023041524A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019114679A (ru) * 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies
IL326387A (en) * 2023-09-14 2026-04-01 Hoffmann La Roche Antibody formulation
WO2025186235A1 (en) 2024-03-05 2025-09-12 H. Lundbeck A/S Compositions and methods for treating multiple system atrophy (msa)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2361928T3 (en) * 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017176835A2 (en) * 2016-04-06 2017-10-12 Imago Pharmaceuticals, Inc. Therapeutic antibodies for treatment of neurodegeneration
RU2019114679A (ru) * 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
JOP20190227A1 (ar) * 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies

Similar Documents

Publication Publication Date Title
JP7080263B2 (ja) 高濃度の抗vegf抗体を含有する安定状態のタンパク質溶液製剤
US20230047111A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
JP2024099682A5 (cg-RX-API-DMAC7.html)
JP2020506924A5 (cg-RX-API-DMAC7.html)
IL311344A (en) Preparations and methods for the treatment of synoclinopathies
JP2017160208A5 (cg-RX-API-DMAC7.html)
CN106061468B (zh) 包含TNFR和Fc区的融合蛋白的液体制剂
TWI857996B (zh) 含高濃度抗vegf抗體之蛋白質溶液配製物
RU2018107725A (ru) Стабильный состав на основе антитела к ifnar1
FI3576788T3 (fi) Matalan ph-arvon omaava farmaseuttinen koostumus, joka käsittää t-soluihin sitoutuvia vasta-ainekonstrukteja
JP7398958B2 (ja) 安定的抗osmr抗体製剤
JP2022513684A5 (cg-RX-API-DMAC7.html)
US20250073170A1 (en) High concentration formulations of anti-csf1 and anti-csf1r antibodies
JP2020510079A (ja) 抗TNFα抗体の液状製剤
JP2015535237A (ja) Tnfr:fc融合プロテインの安定な医薬組成物
JP2018531980A (ja) 抗d因子抗体製剤
JP2018532693A5 (cg-RX-API-DMAC7.html)
JP2018536650A5 (cg-RX-API-DMAC7.html)
JP2018501311A (ja) 液体医薬組成物
RU2024106395A (ru) Композиции и способы для лечения синуклеинопатий
TWI775827B (zh) 水性製劑及裝入注射器之水性製劑以及抗體蛋白去凝集劑及抗體蛋白去凝集方法
JP2025515205A5 (cg-RX-API-DMAC7.html)
US20250215086A1 (en) Anti-pd-1 antibody formulations
TWI887362B (zh) 抗內皮脂肪酶抗體之配製物
JP2023514721A5 (cg-RX-API-DMAC7.html)